Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer

International Journal of Biological Markers

Volumn 27, Issue 2, 2012, Pages 132-138

  Ai, Ting ^a   Wang, Zhouquan ^b   Zhang, Mingxin ^a   Zhang, Lingmin ^a   Wang, Ning ^c   Li, Weiwei ^c   Song, LiPing ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Sengong Hospital   (China)

^c Xi Jing Hospital   (China)

Author keywords

Cyclin D1; Non small cell lung cancer; Signal transducer and activator of transcription 3

Indexed keywords

CYCLIN D1; STAT3 PROTEIN;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84871064889     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9146     Document Type: Article

References (23)

1. Alberg AJ, Ford JG, Samet JM. American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 29S-55S.
2. Mirshahidi HR, Hsueh CT. Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 2010; 3: 18.
3. Secko D. Cancer therapy finds a solid target. CMAJ 2005; 173: 246.
4. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
5. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251: 199-210.
6. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006; 66: 3162-3168.
7. Ng DC, Lin BH, Lim CP, et al. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol 2006; 172: 245-257.
8. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65: 939-947.
9. Gugger M, Kappeler A, Vonlanthen S, et al. Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer 2001; 33: 229-239.
10. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-109.
11. Khoury T, Alrawi S, Ramnath N, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009; 10: 58-66.
12. Esposito V, Baldi A, De Luca A, et al. Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer. J Clin Pathol 2005; 58: 734-739.
13. Sterlacci W, Fiegl M, Hilbe W, et al. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010; 5: 1325-1336.
14. Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001; 8: 737-743.
15. Volm M, Koomägi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer 2000; 82: 1747-1754.
16. Poincloux L, Durando X, Seitz JF, et al. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg Oncol 2009; 18: 357-365.
17. Leslie K, Gao S P, Berishaj M, et al. Differential interleukin-6/ Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res 2010; 12: R80.
18. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006; 2006: pe30.
19. Achcar Rde O, Cagle PT, Jagirdar J. Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 2007; 131: 1350-1360.
20. Dworakowska D, Jassem E, Jassem J, et al. Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J Cancer Res Clin Oncol 2005; 131: 479-485.
21. Yin Z, Zhang Y, Li Y, Lv T, Liu J, Wang X. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem. 2012; 114: 151-158.
22. Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 2007; 55: 349-355.
23. Galleges Ruiz MI, Floor K, Steinberg SM, et al. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 2009; 100: 145-152.